About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Long Covid
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Mpox (Monkeypox)
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
Broad Spectrum Antivirals
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
All SEC Filings
Investors
Investors
Overview
News & Events
Tonix in the News
Press Releases
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Filing Type:
View All
10-K
10-K/A
10-Q
3
4
4/A
424B3
424B4
424B5
5
8-A12B
8-A12G
8-K
8-K/A
ARS
AW
CERTNAS
CORRESP
CT ORDER
D
D/A
DEF 14A
DEFA14A
EFFECT
FWP
NT 10-K
POS AM
POS EX
PRE 14A
RW
S-1
S-1/A
S-3
S-3/A
S-3MEF
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC 14F1
SEC STAFF LETTER
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Date
Form
Description
PDF
XBRL
Pages
11/25/19
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
9
11/25/19
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
10
11/22/19
8-K
Current report filing
Documents
expand_more
EX-99.01
EX-99.02
8
11/20/19
8-K
Current report filing
Documents
expand_more
EX-99.01
5
11/18/19
424B4
Prospectus filed pursuant to Rule 424(b)(4)
41
11/15/19
8-K
Current report filing
Documents
expand_more
EX-3.01
EX-4.01
EX-4.02
EX-99.01
59
11/14/19
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
11/14/19
EFFECT
Notice of Effectiveness
1
11/14/19
S-1/A
General form of registration statement for all companies including face-amount certificate companies
51
11/14/19
8-K
Current report filing
3
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
…
Page
49
Page
50
Page
51
Page
52
Page
53
Page
54
Page
55
Page
56
Page
57
Page
58
…
…
Page
131
Next Page
arrow_forward